OptiScan Stock

optiscancorp.comHealthcareFounded: 1900Funding to Date: $207.05MM

Optiscan Biomedical is the developer of a monitoring platform for use in hospital intensive care units (ICUs) to support clinicians in detecting changes more rapidly in critically ill patients, enabling more timely intervention.

Register for Details

For more details on financing and valuation for OptiScan, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for OptiScan.

Register Today
Register for Details

For more details on financing and valuation for OptiScan, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Cary Vance
Chief Executive Officer, President & Board Member
Patrick Nugent
Chief Financial Officer
Carlo Mata
Director of Marketing
Jim Causey
Vice President, Research & Development

Board Members

Aditya Puri
Xeraya Capital
Charles Liamos
MedVenture Associates
Kenneth Abramowitz
NGN Capital
Paul Mieyal Ph.D
Wexford Capital
Phillip Stern
Chartline Capital Partners

Other companies like OptiScan in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$1.33B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$67.5MM
Sector
Last Round Est. Valuation
$1.4B
Sector
Last Round Est. Valuation
$885.01MM
Sector
Last Round Est. Valuation
$1.65B
Sector
Last Round Est. Valuation
$8.18B

News

OptiScan Biomedical Announces Peer-Reviewed Publications Highlighting First-of-its-Kind Continuous Monitoring Platform for Intensive Care Units - read this article along with other careers information, tips and advice on BioSpace
OptiScan Biomedical, a developer of an innovative continuous monitoring system for use in the surgical intensive care unit, closed $20m Series E financing
OptiScan Biomedical said today that it closed a $20 million Series E round to support the commercialization of its continuous monitoring system, the OptiScanner 5000, in the U.S. The company’s device is an automated bedside blood glucose monitor designed for use in the intensive care unit. The system can measure glucose values from a micro-sample of […]